… The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …

… Erlotinib is a human epidermal growth factor receptor Type 1/EGFR tyrosine kinase inhibitor.
Erlotinib monotherapy is … Erlotinib monotherapy has shown a significant improvement in …

… To evaluate the efficacy and safety of erlotinib for non-small … The study involved 307 patients
treated with erlotinib at 14 … Although 45.6% of the patients in this study received erlotinib …

… the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy … the role of gefitinib or erlotinib
in advanced non-small cell … The results show that monotherapy therapy with EFGR-TKIs …

… contrast the efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone
… trials (RCTs) comparing erlotinib plus bevacizumab with erlotinib in NSCLC patients. The …

… Objectives Bevacizumab and erlotinib inhibit different tumour … , the efficacy of bevacizumab
in combination with erlotinib … and erlotinib to bevacizumab or erlotinib monotherapy in the …

… In conclusion, erlotinib was safe and effective for treating … Efficacy and safety of erlotinib
monotherapy for Japanese … High efficacy of erlotinib in Taiwanese NSCLC patients in an …

… We aimed to evaluate the efficacy and safety of erlotinib monotherapy as third-line chemotherapy
in patients with advanced non-small-cell lung cancer without epidermal growth factor …

… This report represents the first analysis of OS benefit with the combination of erlotinib
plus bevacizumab vs erlotinib monotherapy in EGFR+ NSCLC. The significant PFS benefit …

… The aim of this study conducted by the Korean Cancer Study Group was to evaluate the
efficacy and tolerability of erlotinib monotherapy as a palliative treatment for advanced NSCLC …